Our Pricing

Is Ozempic Insulin? Understanding the Difference

A common question we receive at Cured Pharmacy is: is Ozempic insulin? The short answer is no — Ozempic (semaglutide) is a GLP-1 receptor agonist, not insulin, though both are injectable medications used to manage type 2 diabetes. Understanding the distinction between these treatments is essential for making informed decisions about your diabetes care alongside your UK prescriber.

What Is Ozempic and How Does It Differ from Insulin?

Ozempic contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that works by mimicking a natural hormone your body produces after eating [1]. Unlike insulin, which directly replaces or supplements the hormone your pancreas produces to lower blood sugar, Ozempic stimulates your own pancreas to release insulin only when blood glucose levels are elevated. This glucose-dependent mechanism significantly reduces the risk of hypoglycaemia compared to insulin therapy.

The key distinction is that insulin is a replacement hormone therapy, whilst Ozempic is a medication that enhances your body's own insulin response. Ozempic also slows gastric emptying and reduces appetite, contributing to weight loss — an effect not seen with traditional insulin treatments [2]. In the SUSTAIN clinical trial programme, patients taking semaglutide achieved an average HbA1c reduction of 1.5–1.8% alongside meaningful weight loss, whereas insulin therapy typically causes weight gain [1][2].

Both medications are administered by injection, which often causes confusion. However, the pharmacological mechanisms, side effect profiles, and clinical indications differ substantially. Your UK prescriber will determine which treatment — or combination of treatments — is most appropriate based on your individual diabetes progression, current HbA1c levels, and overall health status.

Can You Take Insulin and Ozempic Together?

Yes, many patients with type 2 diabetes use insulin and Ozempic concurrently, particularly when oral medications and GLP-1 therapy alone no longer provide adequate glycaemic control [3]. This combination approach is supported by NICE guidelines and is commonly prescribed when diabetes has progressed to a stage requiring both basal insulin support and the glucose-dependent insulin secretion that GLP-1 agonists provide.

When starting Ozempic alongside existing insulin therapy, your prescriber will typically reduce your insulin dose to minimise the risk of hypoglycaemia, as both medications lower blood glucose. Clinical studies demonstrate that adding semaglutide to insulin regimens can improve HbA1c control whilst allowing for insulin dose reduction and promoting weight loss — a significant benefit given that insulin therapy often leads to weight gain [3][4].

It's essential to monitor your blood glucose levels closely when using both treatments together, especially during the initial titration period. Your UK prescriber will provide specific guidance on dose adjustments, and you should never alter your insulin regimen without professional consultation. At Cured Pharmacy, our clinical team works alongside your existing diabetes care to ensure safe, coordinated treatment.

Monitoring and Dose Adjustments

When combining these therapies, regular blood glucose monitoring becomes particularly important. Your prescriber may recommend checking levels more frequently during the first few weeks to identify patterns and adjust doses accordingly. Most patients find that their insulin requirements decrease as Ozempic reaches therapeutic levels, but this reduction must be managed carefully under medical supervision to avoid both hypo- and hyperglycaemia.

Is Ozempic Insulin or a Diabetes Medication Alternative?

To clarify further: is Ozempic insulin? No — Ozempic is classified as a GLP-1 receptor agonist, representing a distinct class of diabetes medication. Whilst insulin directly lowers blood glucose by facilitating cellular glucose uptake, Ozempic works through multiple complementary mechanisms: stimulating glucose-dependent insulin secretion, suppressing inappropriate glucagon release, slowing gastric emptying, and reducing appetite [1].

For many patients with type 2 diabetes, Ozempic may delay or reduce the need for insulin therapy, particularly when introduced earlier in the disease progression. The SUSTAIN-6 cardiovascular outcomes trial demonstrated that semaglutide not only improved glycaemic control but also reduced major adverse cardiovascular events by 26% compared to placebo — a benefit not consistently seen with all insulin formulations [5].

However, Ozempic is not appropriate for everyone. Patients with type 1 diabetes require insulin therapy, as their pancreas produces little to no insulin. Additionally, some individuals with advanced type 2 diabetes and severely impaired pancreatic function may need insulin as their primary treatment. Your UK prescriber will assess your C-peptide levels, diabetes duration, and beta-cell function to determine the most suitable therapeutic approach.

Weight Loss Benefits: Ozempic vs Insulin Therapy

One of the most significant clinical differences between asking 'is Ozempic insulin' relates to weight management. Insulin therapy, whilst essential for many patients, typically causes weight gain averaging 2–4 kg over the first year of treatment [2]. This occurs because insulin promotes glucose storage and can increase appetite, making weight management challenging for patients already struggling with obesity-related type 2 diabetes.

In contrast, semaglutide-based treatments like Ozempic and Wegovy have demonstrated substantial weight loss in clinical trials. The STEP trial programme showed that patients using semaglutide 2.4 mg (the Wegovy dose) achieved an average weight reduction of 15–17% over 68 weeks [6]. Even at the lower Ozempic doses used for diabetes management, patients typically experience meaningful weight loss rather than gain.

At Cured Pharmacy, we offer several GLP-1 options for weight management, subject to prescriber approval. Wegovy (semaglutide) is available from £135.00, whilst Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist showing even greater weight loss in clinical trials, starts from £135.00. Both require a clinical assessment by our UK prescribers, and prices are transparent before you begin your consultation.

Choosing Between Weight Loss Treatments

Your prescriber will consider your BMI, diabetes status, cardiovascular risk factors, and previous treatment responses when recommending a GLP-1 medication. Mounjaro has demonstrated superior weight loss outcomes in head-to-head trials against semaglutide, with patients achieving up to 22.5% body weight reduction in the SURPASS-3 trial [7]. However, individual responses vary, and the best treatment is the one you can tolerate and adhere to long-term.

Side Effects: Comparing Ozempic and Insulin

The side effect profiles of these medications differ considerably, which often influences treatment selection. Insulin's primary risk is hypoglycaemia — potentially dangerous low blood sugar episodes that can cause confusion, sweating, tremors, and in severe cases, loss of consciousness. This risk increases with higher insulin doses and is particularly concerning for patients with irregular eating patterns or those who exercise intensively [3].

Ozempic carries a much lower hypoglycaemia risk when used alone, as its glucose-dependent mechanism means insulin secretion only increases when blood sugar is elevated [1]. However, the most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation. These effects are usually temporary and can be managed by following the gradual titration schedule and eating smaller, more frequent meals [4].

Both medications require injection, though the frequency differs — Ozempic is administered once weekly, whilst most insulin regimens require daily or multiple daily injections. Some patients find the weekly dosing schedule more convenient and easier to maintain long-term. Rare but serious side effects of GLP-1 agonists include pancreatitis and potential thyroid concerns, which your prescriber will discuss during your clinical assessment.

Getting Ozempic or Alternative Treatments at Cured Pharmacy

If you're considering GLP-1 therapy for diabetes management or weight loss, Cured Pharmacy offers a streamlined, discreet service with transparent pricing. Whilst we don't currently stock Ozempic specifically, we provide clinically equivalent and superior alternatives including Wegovy (semaglutide) from £135.00 and Mounjaro (tirzepatide) from £135.00, both subject to prescriber approval following your free online consultation.

Our process is straightforward: complete a brief medical questionnaire (under 3 minutes), which is reviewed by our UK-registered clinical team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073). If approved, your prescription is dispensed from our GPhC-registered pharmacy (9012511) and delivered discreetly to your door. All medications are genuine, UK-licensed products — we never supply unlicensed or imported alternatives.

For patients currently using insulin who are interested in adding GLP-1 therapy, we recommend discussing this with your existing diabetes care team first to ensure coordinated treatment. Our prescribers can then work within your overall diabetes management plan to provide safe, effective add-on therapy. You can explore our full range of weight loss treatments, including Saxenda (liraglutide) from £135.00 and oral options like Orlistat from £135.00, at our weight loss collection.

Why Choose Cured Pharmacy for Diabetes and Weight Loss Treatments

We guarantee the lowest prices in the UK, with upfront pricing displayed before you begin your consultation — no hidden fees or surprise charges. Our 100% discreet packaging ensures your privacy, and our UK-based clinical team is available by phone on (+44) 116 4646009 if you have questions about your treatment. Every prescription medication requires clinical assessment, ensuring you receive safe, appropriate care tailored to your individual health needs.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Davies, M. J., et al. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
3. NHS. (2024). Semaglutide (Ozempic, Wegovy). NHS UK. https://www.nhs.uk/medicines/semaglutide/
4. Aroda, V. R., et al. (2019). Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. The Lancet Diabetes & Endocrinology, 7(5), 356–367. https://doi.org/10.1016/S2213-8587(19)30085-2
5. Marso, S. P., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834–1844. https://doi.org/10.1056/NEJMoa1607141
6. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
7. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.